Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2026
Reporting Period: Event date March 17, 2026
Business Context: The registrant is a Delaware corporation listed on the Nasdaq Capital Market. It is classified as an emerging growth company. The filing reports the release of a new clinical case study regarding its CyPath® Lung noninvasive test for lung cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses on a non-financial operational update: the publication of a clinical case study demonstrating the diagnostic benefits of CyPath® Lung for high-risk patients with multiple pulmonary nodules.
Guidance, Outlook, and Risks
Management Commentary: The company announced a new clinical case study highlighting the utility of CyPath® Lung in the diagnostic pathway for lung cancer.
Guidance/Outlook: The filing text does not provide a clear value for future financial guidance or operational outlook.
Risks/Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 to understand the specific clinical findings.
- Confirm the status of the CyPath® Lung test in the regulatory approval pipeline.
- Review recent 10-K or 10-Q filings for the most current financial position, as this 8-K contains no financial data.
- Monitor Nasdaq Capital Market trading for BIAF and BIAFW (warrants) for market reaction to the clinical study announcement.